Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
Axogen (NASDAQ: AXGN) announced preliminary unaudited revenue figures for Q4 and the full year 2024. The company expects fourth-quarter revenue of approximately $49.4 million, a 15.1% increase from Q4 2023. Full-year revenue is anticipated to be around $187.3 million, a 17.8% increase over 2023. This growth is attributed to improved execution of commercial strategies and increased adoption of Axogen's surgical solutions, particularly in Extremities and OMF-Head & Neck applications, as well as Resensation® for post-mastectomy breast reconstruction. Axogen projects a full-year gross margin above 75.5% and expects its cash, cash equivalents, and investments to total around $39.5 million by year-end, up $2.5 million from 2023. CEO Michael Dale expressed satisfaction with the company's performance and announced an Investor Day on March 4th, 2025, to share future strategic priorities. The results are preliminary and unaudited, with full audited results expected to be reported on or before Investor Day.
Axogen (NASDAQ: AXGN) ha annunciato i dati preliminari delle entrate non verificate per il quarto trimestre e per l'intero anno 2024. L'azienda prevede che le entrate del quarto trimestre saranno di circa 49,4 milioni di dollari, con un incremento del 15,1% rispetto al quarto trimestre 2023. Le entrate per l'intero anno sono stimate intorno ai 187,3 milioni di dollari, con un aumento del 17,8% rispetto al 2023. Questa crescita è attribuita a un miglioramento nell'esecuzione delle strategie commerciali e a un aumento nell'adozione delle soluzioni chirurgiche di Axogen, in particolare nelle applicazioni di estremità e OMF-Head & Neck, oltre a Resensation® per la ricostruzione mammaria post-mastectomia. Axogen prevede un margine lordo per l'intero anno superiore al 75,5% e si aspetta che la liquidità, i mezzi equivalenti e gli investimenti ammontino a circa 39,5 milioni di dollari entro la fine dell'anno, con un incremento di 2,5 milioni di dollari rispetto al 2023. Il CEO Michael Dale ha espresso soddisfazione per le performance dell'azienda e ha annunciato un Investor Day il 4 marzo 2025 per condividere le future priorità strategiche. I risultati sono preliminari e non verificati, con i risultati finali attesi entro o prima dell'Investor Day.
Axogen (NASDAQ: AXGN) anunció cifras preliminares de ingresos no auditados para el cuarto trimestre y el año completo 2024. La compañía espera que los ingresos del cuarto trimestre sean de aproximadamente 49.4 millones de dólares, un aumento del 15.1% en comparación con el cuarto trimestre de 2023. Los ingresos anuales se anticipan en alrededor de 187.3 millones de dólares, un incremento del 17.8% respecto a 2023. Este crecimiento se atribuye a una mejor ejecución de las estrategias comerciales y un mayor uso de las soluciones quirúrgicas de Axogen, particularmente en aplicaciones de extremidades y OMF-Cabeza y Cuello, así como Resensation® para la reconstrucción mamaria post-mastectomía. Axogen proyecta un margen bruto anual superior al 75.5% y espera que su efectivo, equivalentes de efectivo e inversiones totalicen alrededor de 39.5 millones de dólares para fin de año, un aumento de 2.5 millones de dólares en comparación con 2023. El CEO Michael Dale expresó su satisfacción con el desempeño de la compañía y anunció un Investor Day el 4 de marzo de 2025 para compartir las prioridades estratégicas futuras. Los resultados son preliminares y no auditados, con resultados completos que se espera se informen antes o el mismo día del Investor Day.
Axogen (NASDAQ: AXGN)은 2024년 4분기 및 전체 연도의 예비 미검토 수익 수치를 발표했습니다. 회사는 4분기 수익이 약 4,940만 달러로 2023년 4분기 대비 15.1% 증가할 것으로 예상하고 있습니다. 전체 연도 수익은 약 1억 8,730만 달러로 2023년 대비 17.8% 증가할 것으로 보입니다. 이러한 성장은 상업 전략의 실행 개선과 Axogen의 외과 솔루션, 특히 사지 및 OMF-머리와 목 응용 프로그램, 그리고 유방 절제 후 재건을 위한 Resensation®의 채택 증가에 기인합니다. Axogen은 연간 총 매출 총 이익률이 75.5% 이상일 것으로 예상하며, 현금, 현금 등가물 및 투자 총액이 연말까지 약 3,950만 달러에 이를 것으로 보며, 이는 2023년 대비 250만 달러 증가한 수치입니다. CEO인 Michael Dale은 회사의 성과에 대한 만족감을 표명했으며, 2025년 3월 4일에 향후 전략적 우선 사항을 공유하기 위한 Investor Day를 발표했습니다. 결과는 예비 수치이며 감사되지 않았으며, 전체 감사 결과는 Investor Day 전이나 그날에 발표될 예정입니다.
Axogen (NASDAQ: AXGN) a annoncé des chiffres préliminaires de revenus non audités pour le quatrième trimestre et l'année entière 2024. L'entreprise s'attend à un chiffre d'affaires d'environ 49,4 millions de dollars pour le quatrième trimestre, soit une augmentation de 15,1 % par rapport au quatrième trimestre 2023. Les revenus pour l'année complète devraient être d'environ 187,3 millions de dollars, soit une augmentation de 17,8 % par rapport à 2023. Cette croissance est attribuée à une meilleure exécution des stratégies commerciales et à une adoption croissante des solutions chirurgicales d'Axogen, particulièrement dans les applications des extrémités et OMF-Tête & Cou, ainsi que Resensation® pour la reconstruction mammaire après mastectomie. Axogen projette un bénéfice brut annuel supérieur à 75,5 % et s'attend à ce que sa trésorerie, ses équivalents de liquidités et ses investissements totalisent environ 39,5 millions de dollars d'ici la fin de l'année, soit 2,5 millions de dollars de plus qu'en 2023. Le PDG Michael Dale a exprimé sa satisfaction quant à la performance de l'entreprise et a annoncé un Investor Day le 4 mars 2025 pour partager les priorités stratégiques futures. Les résultats sont préliminaires et non audités, les résultats complets étant attendus au plus tard le jour de l'Investor Day.
Axogen (NASDAQ: AXGN) hat vorläufige, nicht geprüfte Umsatzahlen für das vierte Quartal und das gesamte Jahr 2024 bekannt gegeben. Das Unternehmen rechnet im vierten Quartal mit einem Umsatz von etwa 49,4 Millionen US-Dollar, was einem Anstieg von 15,1 % im Vergleich zum vierten Quartal 2023 entspricht. Der Umsatz für das gesamte Jahr wird auf etwa 187,3 Millionen US-Dollar geschätzt, was einen Anstieg von 17,8 % im Vergleich zu 2023 darstellt. Dieses Wachstum wird auf eine verbesserte Umsetzung der Geschäftsstrategien und eine verstärkte Annahme der chirurgischen Lösungen von Axogen zurückgeführt, insbesondere in den Bereichen Extremitäten und OMF-Kopf & Hals sowie Resensation® für die rekonstruktive Brustchirurgie nach Mastektomie. Axogen erwartet eine Bruttomarge von über 75,5 % und geht davon aus, dass Bargeld, Zahlungsmitteläquivalente und Investitionen bis Jahresende etwa 39,5 Millionen US-Dollar betragen werden, was einem Anstieg von 2,5 Millionen US-Dollar im Vergleich zu 2023 entspricht. CEO Michael Dale äußerte sich zufrieden über die Leistung des Unternehmens und kündigte einen Investor Day am 4. März 2025 an, um zukünftige strategische Prioritäten zu teilen. Die Ergebnisse sind vorläufig und nicht geprüft, die vollständigen geprüften Ergebnisse werden voraussichtlich am oder vor dem Investor Day veröffentlicht.
- Q4 revenue increase of 15.1% over Q4 2023.
- Full-year 2024 revenue growth of 17.8% compared to 2023.
- Projected full-year gross margin above 75.5%.
- Increase in cash, cash equivalents, and investments by $2.5 million.
- None.
Insights
The preliminary Q4 results showcase impressive growth metrics with
The commercial strategy focusing on high-potential accounts in specialized applications is yielding results. The adoption of Axogen's complete peripheral nerve surgical algorithm across procedures suggests successful market penetration and physician acceptance. The expanded use of Resensation® in post-mastectomy procedures indicates growing market share in a valuable niche.
Key performance indicators point to sustainable growth trajectory: expanding procedure mix, improving operational leverage and healthy cash generation. The upcoming Investor Day could catalyze further investor interest if management presents compelling growth strategies and market expansion plans.
The strategic focus on Extremities and OMF-Head & Neck applications represents intelligent market positioning in high-value surgical segments. The adoption metrics of the peripheral nerve surgical algorithm across multiple procedures indicate growing clinical acceptance and validation of Axogen's approach to nerve repair.
The integration of Resensation® into post-mastectomy breast reconstruction procedures is particularly noteworthy - this represents a significant advancement in addressing quality-of-life outcomes for breast cancer survivors. The
The consistent revenue growth across the product portfolio indicates broad-based clinical adoption rather than dependence on a single product line. This diversification reduces clinical risk and suggests strong validation of the underlying technology platform.
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2024 key financials.
Preliminary Fourth Quarter and Year-End Key Business Highlights
- Fourth quarter revenue is expected to be approximately
$49.4 million , which represents a15.1% increase over the fourth quarter of 2023 driven by solid performance across the product portfolio. - Full-year 2024 revenue is expected to be approximately
$187.3 million , which represents a17.8% increase over the full-year of 2023. - Our positive performance reflects continued improvements in the execution of our commercial strategies, including a focus on high-potential accounts in Extremities and OMF-Head & Neck applications, adoption of Axogen’s complete peripheral nerve surgical algorithm across all procedures, and continued adoption of Resensation® as an expectation for post mastectomy breast reconstruction procedures.
- We expect full year gross margin to be above
75.5% . - Total balance of cash, cash equivalents and investments on December 31, 2024, is expected to be approximately
$39.5 million , representing an increase of approximately$2.5 million over that balance at the end of 2023.
"We are pleased with our fourth-quarter and full-year 2024 performance, which reflects continued improvements in effectiveness and efficiency across the business,” said Michael Dale, President and Chief Executive Officer of Axogen. “Looking to the future, on March 4th, 2025, we look forward to hosting an Investor Day at which we will share our strategic priorities for the future and the work we believe will best advance our mission to make peripheral nerve care, standard-of-care for all patients.”
The results disclosed in this press release are preliminary and unaudited. The Company expects to report full, audited results for the fourth quarter and year ended December 31, 2024, on or before Investor Day.
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Cautionary Statements Concerning Forward-Looking Statements
This press release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects,” “anticipates,” “intends,” “plan(s),” “believes,” “seeks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” “goals,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding our preliminary, unaudited fourth quarter and full year 2024 performance, statements related to our mission of making peripheral nerve care, standard of care for all patients, and statements related to our expectations regarding adoption of breast Resensation®, as well as statements under the subheading " Preliminary Fourth Quarter and Year-End Key Business Highlights." Actual results or events could differ materially from those described in any forward-looking statements as a result of various factors, including, without limitation, potential disruptions caused by leadership transitions, global supply chain issues, record inflation, hospital staffing issues, product development, product potential, expected clinical enrollment timing and outcomes, regulatory process and approvals, APC transition timing and expense, financial performance, sales growth, surgeon and product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events, global business disruption caused by Russia’s invasion of Ukraine and related sanctions, geopolitical conflicts in the Middle East, as well as those risk factors described under Part I, Item 1A., “Risk Factors,” of our Annual Report on Form 10-K for the most recently ended fiscal year and Part II, Item 1A., “Risk Factors,” for our Quarterly Report on Form 10-Q for the most recently ended fiscal quarter. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.
Investor Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com
FAQ
What is the expected revenue for AXGN in Q4 2024?
How much did Axogen's full-year revenue grow in 2024?
What is Axogen's projected gross margin for 2024?
How much cash and investments does Axogen expect to have by the end of 2024?
When will Axogen report its full audited results for 2024?
